Aptahem receives European patent for the protection of patent family 2
Aptahem AB (publ) announces today that the European Patent Office (EPO) has approved the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties. The approval follows the previous provisional approval by the EPO announed on July 5, 2021.The approval by the EPO of patent EP 18783424.7 provides protection for the company’s lead candidate Apta-1 within the patent family 2 in Europe until 2037. Now will the so called validation phase start when the company will decide in which specific European countries to